Science

Giuseppe Banna: WB-MRI vs. CT-Bone Scan in Staging Metastatic Hormone-Sensitive Prostate Cancer

Giuseppe Banna/LinkedIn

May 19, 2025, 08:49

Giuseppe Banna: WB-MRI vs. CT-Bone Scan in Staging Metastatic Hormone-Sensitive Prostate Cancer

Giuseppe Banna, Consultant Medical Oncologist at Portsmouth Hospitals University NHS Trust, shared a post on LinkedIn about a paper he co-authored with colleagues published in Clinical Medicine Insights: Oncology:

“Glad to share our research: WB-MRI vs. CT-Bone Scan in Staging Metastatic Hormone-Sensitive Prostate Cancer (mHSPC). Our latest study reveals critical differences in staging accuracy between whole-body MRI (WB-MRI) and CT-Bone scan (CT-B) for mHSPC patients.

Key findings:

49% vs. 22% classified as high-volume disease (WB-MRI vs. CT-B)

91% vs. 65% identified as de novo metastatic (WB-MRI vs. CT-B)

These disparities may significantly influence treatment decisions in mHSPC and potentially lead to overtreatment with radical surgery/radiotherapy when relying on less sensitive imaging.

Why does this matter? Accurate staging is crucial for optimal therapy selection (e.g., triplet vs. doublet systemic therapy). WB-MRI’s superior detection of bone metastases could refine risk stratification and reduce unnecessary interventions.

A huge thanks to my co-authors and collaborators for their contributions!”

Title: Magnetic Resonance or Computed Tomography and Bone Scan for Staging Metastatic Hormone–Sensitive Prostate Cancer

Authors: Mona Ali Hassan, Shobana Anpalakhan, Marina Campione, Akash Maniam, Naoko Atsumi, Shyamika Acharige, Utku Lokman, Hajra Iqbal, Tomasz Olejnik, Maja Uherek, Daniel Wilby, Richard Robinson, Joanna Buckley, Joanna Gale, and Giuseppe Luigi Banna.

You can read the Full Article in Clinical Medicine Insights: Oncology.

More posts featuring Giuseppe Banna.

Akash Maniam bone scan cancer computed tomography Daniel Wilby Giuseppe Banna Hajra Iqbal Joanna Buckley Joanna Gale Maja Uherek Marina Campione mHSPC Mona Ali Hassan MRI Naoko Atsumi OncoDaily Oncology prostate cancer Richard Robinson Shobana Anpalakhan Shyamika Acharige Tomasz Olejnik Utku Lokman WB-MRI

Joe Biden Diagnosed with Aggressive Metastatic Prostate Cancer at Age 82

DESTINY-Breast06 Trial Updates at ESMO Breast 2025 Confirms T-DXd Efficacy in HER2-Low and Ultralow Metastatic Breast Cancer

FDA Approves Belzutifan (Welireg) for Advanced Pheochromocytoma and Paraganglioma: Results of LITESPARK-015 Trial

New World Cancer Declaration 2025–2035 by UICC

Agenus Bets Big on Botensilimab